Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer

Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer

Abstract. Background:. Durvalumab after chemoradiotherapy (CRT) failed to bring survival benefits to patients with epidermal growth factor receptor (EGFR) mutations in PACIFIC study (evaluating durvalumab in patients with stage III, unresectable NSCLC who did not have disease progression after conc...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xin Dai, Qian Xu, Lei Sheng, Xue Zhang, Miao Huang, Song Li, Kai Huang, Jiahui Chu, Jian Wang, Jisheng Li, Yanguo Liu, Jianyuan Zhou, Shulun Nie, Lian Liu, Jing Ni
Format:	Article
Language:	English
Published:	Wolters Kluwer 2025-07-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000003386
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial
by: Dongliang Bian, et al.
Published: (2025-04-01)

Exciting progress in targeted therapy innovation for unresectable stage III EGFR‐mutated NSCLC: the phase III LAURA study
by: Ziyan Tong, et al.
Published: (2024-12-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC
by: Sebastian Kraus
Published: (2024-10-01)

Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
by: Linwu Kuang, et al.
Published: (2025-03-01)

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
by: Ning Lou, et al.
Published: (2024-12-01)

High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy
by: Shugui Wu, et al.
Published: (2025-05-01)

Biased signaling by mutant EGFR underlies dependence on PKCα in lung adenocarcinoma
by: Mojtaba Sadeghi, et al.
Published: (2024-12-01)

Correlation analysis on epidermal growth factor receptor (EGFR) mutations and clinicopathological characteristics in lung adenocarcinomas
by: Haitao Wang, et al.
Published: (2025-03-01)

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01)

Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis
by: Wengang Zhang, et al.
Published: (2025-05-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Soomin Kim, et al.
Published: (2025-02-01)

EGFRp4 Peptides: A Novel Strategy for Epidermal Growth Factor Receptor (EGFR) Inhibitor
by: Nattanan Jiwacharoenchai, et al.
Published: (2025-06-01)

Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor–tyrosine kinase inhibitors
by: Huang-Chih Chang, et al.
Published: (2017-03-01)

MOLECULAR DOCKING SIMULATIONS ON EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH POTENTIAL LEAD MOLECULES
by: K Ganesh Kadiyala, et al.
Published: (2025-03-01)

Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage
by: Sandra Rayego-Mateos, et al.
Published: (2018-01-01)

M6A Methylation Regulators METTL3 and ALKBH5 are Risk Factors for EGFR-Mutant NSCLC
by: Yaofeng Zhi MMed, et al.
Published: (2025-05-01)

RETRACTED: De Novo HER2 S310Y mutation associates with poor response to EGFR tyrosine kinase inhibitor in activating EGFR-mutant NSCLC patient: A case report
by: Fei Gao, et al.
Published: (2019-02-01)

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
by: Luo FX, et al.
Published: (2025-04-01)

Adequacy of biopsy samples for epidermal growth factor receptor (EGFR) molecular testing in lung adenocarcinoma
by: Tegeltija Dragana, et al.
Published: (2021-01-01)

Perioperative Treatment in EGFR‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives
by: Xiaobei Guo, et al.
Published: (2025-02-01)

Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports
by: Blerina Resuli, MD, et al.
Published: (2024-12-01)

EGFR-mutant lung adenocarcinoma transformed into small cell Lung cancer: A case report and literatures review
by: Jinhong Chen, et al.
Published: (2025-01-01)

What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review
by: Chuang Yang, et al.
Published: (2025-08-01)

Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia
by: Chun-xiao Hou, et al.
Published: (2024-12-01)

Optimal intervention timing for craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastases
by: Guangchuan Deng, et al.
Published: (2024-12-01)

Advancing multimodal predictive models for targeted therapy response in EGFR-mutant lung adenocarcinoma: opportunities and challenges
by: Lina Song, et al.
Published: (2025-05-01)

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01)

Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication
by: Ghulam Raza, et al.
Published: (2025-03-01)

Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy
by: Ying Wu, et al.
Published: (2024-04-01)

Deep learning radiopathomics predicts targeted therapy sensitivity in EGFR-mutant lung adenocarcinoma
by: Taotao Yang, et al.
Published: (2025-04-01)

EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives
by: Antonio Rossi, et al.
Published: (2022-12-01)

Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth
by: Rui Zhou, et al.
Published: (2024-12-01)

Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: a retrospective multi-institutional analysis
by: Mingfeng He, et al.
Published: (2025-01-01)

Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure
by: Zong-Han Yao, et al.
Published: (2025-08-01)

The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients
by: N. N. Babyshkina, et al.
Published: (2020-04-01)

Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors
by: Chih-Yen Tu, et al.
Published: (2024-01-01)

Exploring the role of epidermal growth factor receptor variant III in meningeal tumors.
by: Rashmi Rana, et al.
Published: (2021-01-01)

Epidermal Growth Factor Downregulates Carbon Anhydrase III (CAIII) in Colon Cancer
by: Derya Okuyan
Published: (2024-11-01)

Triple reversal phenomenon in EGFR-mutant lung adenocarcinoma with prostate metastasis following hepatocellular carcinoma: a rare Case Report with diagnostic and therapeutic implications
by: Jieyan Luo, et al.
Published: (2025-07-01)